We listen,
learn, and
deliver.
To those lacking effective treatment options: We hear you. And we are relentlessly driving toward much-needed solutions.
Tisento means “I hear you” in Italian.
At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company.
We are on a mission to deliver medicines that address what matters most.
Our Commitment to MELAS
Understanding & Addressing the Unmet Need
We are dedicated to listening deeply to people with MELAS (Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes) and to acting with urgency in response. MELAS affects multiple organ systems, especially organs that require significant energy like the brain and muscles. This results in severe and burdensome symptoms including chronic fatigue, cognitive dysfunction, muscle weakness, seizures, and stroke-like episodes. MELAS is also associated with a shortened life expectancy. We are committed to advancing zagociguat, potentially the first treatment for people living with MELAS.
Zagociguat
Building on Encouraging Phase 2a Data in MELAS Patients
Our investigational medicine, zagociguat, is an oral, once-daily, first-in-class, brain-penetrant soluble guanylate cyclase (sGC) stimulator. Zagociguat acts directly and exclusively on the central node of a key biological signaling pathway: NO-sGC-cGMP. This pathway, which is dysregulated in MELAS, plays an essential role in fundamental physiological processes, including mitochondrial biogenesis and function, neuroprotection, and vascular homeostasis.
In a Phase 2a study in patients with MELAS, zagociguat exhibited an excellent safety profile, exposure throughout the body including in the central nervous system, and improvements across key domains of the disease pathophysiology including neuronal function, mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes.
We are laser-focused on advancing a Phase 2b program of zagociguat in MELAS to deliver a potential new option for patients as quickly as possible.
MELAS Interview Study
We’ve completed enrollment of adults into our MELAS interview study, and enrollment is NOW OPEN to adolescents with MELAS (12-17yrs). The goal of this study is to better understand the most burdensome symptoms and quality-of-life impacts of MELAS from those living with the disease. This will shape how the effects of zagociguat will be assessed.
Inspired by patients and a shared hope for a better future, we are undertaking our mission with urgency and decisiveness. We are poised to deliver at an accelerated pace.
News
Our Team
With our committed team of industry veterans and our expansive network, we are advancing zagociguat as a potential treatment for individuals with MELAS, a debilitating disease for which no approved treatment exists.
At Tisento, we don’t back down from a challenge. Inspired by the perseverance of those with limited treatment options, we push forward with tenacity in the hope of enabling a better future for patients and their loved ones.